Sanoculis News
7 articles
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, has received CE Mark approval under the Medical Device Regulation (MDR) in the EU for its MINT® product. MINT® is a stent-free technology platform designed for glaucoma angle surgery, offering a less invasive and more effective treatment option. The approval marks a significant milestone for Sanoculis, allowing them to proceed with a selective commercial pre-launch rollout later this year. The MINT® technology has shown promising results in clinical studies, indicating its safety and effectiveness in lowering intraocular pressure and reducing the need for glaucoma medications. This development is expected to enhance the standard of care for glaucoma patients.
Product Stage
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, has received CE Mark approval in the EU for its MINT® (Minimally Invasive Nasal Trabeculostomy) product. This innovative, stent-free technology platform is designed for the treatment of glaucoma and aims to improve patient outcomes by offering a less invasive, more effective treatment option. Clinical data indicates that MINT® is safe and effective in lowering intraocular pressure and reducing the need for glaucoma medications. Sanoculis plans a selective commercial pre-launch rollout of the MINT® technology later this year. The approval marks a significant step forward for the company, potentially elevating the standard of care in glaucoma treatment.
Product Stage
Growth-Positive
Eckuity Joins Bausch + Lomb in an Equity Investment in Sanoculis
Eckuity, a venture capital investor based in New York and London, has invested in Sanoculis, an Israeli ophthalmic medical device company, as part of a Series C funding round. Bausch + Lomb also invested and entered into an exclusive European distribution agreement with Sanoculis for its Minimally Invasive Micro Sclerostomy (MIMS®), a surgical procedure for glaucoma treatment. The companies have also entered into an option agreement, giving Bausch + Lomb the option to purchase all of Sanoculis assets.
InvestmentPartnersAcquisition
growth-positive
Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma
Bausch + Lomb Corporation has made an equity investment in Sanoculis, an Israeli ophthalmic medical device start-up, as part of a Series C funding round. The companies have also entered into an exclusive European distribution agreement for Sanoculis Minimally Invasive Micro Sclerostomy (MIMS), a surgical procedure for the treatment of glaucoma. The partnership aims to address unmet needs in glaucoma treatment, with MIMS offering a stentless, simple, and fast treatment that lowers intraocular pressure without invasive surgery. The companies have also entered into an option agreement, giving Bausch + Lomb the option to purchase all of Sanoculis assets.
InvestmentPartners
Neutral
News - Eyewire+
Eyewire+ is a platform that provides updates on the latest developments in the ophthalmic field. The information is sourced from press releases, medical journals, vision publications, videos, and other news sources.
growth-positive
Alfred Mann's legacy stimulates Israeli innovation
The Mann Foundation for Biomedical Engineering and the Alfred Mann Institute at the Technion, both part of the legacy of late billionaire philanthropist and medical equipment entrepreneur Alfred Mann, are continuing to support medical equipment startups following Manns death. The Mann Foundation manages two funds that encourage applied research into startups at two universities, including the Technion Israel Institute of Technology. The foundation currently manages $85m and expects to increase this to $400m in the next two to three years.
InvestmentExpand
growth-positive
Minimally invasive micro sclerostomy may be alternative to trabeculectomy
Sanoculis, a medical technology company, has developed a new surgical technique called Minimally Invasive Micro Sclerostomy (MIMS) for treating patients with glaucoma. The technique combines the mechanism of conventional trabeculectomy and simple needling, and is designed to control intraocular pressure (IOP) with fewer complications. Preliminary trials of the MIMS procedure have shown promising results in primary open-angle glaucoma patients, with a 95.5% success rate in creating a drainage channel. However, long-term IOP control and morphological variations induced by conjunctival or sclera fibrotic changes need to be evaluated in future studies.
Customers
